Study Evaluating Diltiazem in Combination With Standard Treatment in the Management of Patients Hospitalized With COVID-19 Pneumonia

COVID-19 Clinical Trial

— DICOV  

Official title:

Multicenter, Double-blind, Randomized, Placebo-controlled Study Evaluating Diltiazem in Combination With Standard Treatment in the Management of Patients Hospitalized With COVID-19 Pneumonia - A Phase IIB, Proof of Concept Study

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT05563168
• Other study ID #: 69HCL21_0855
• Secondary ID: 2021-004160-94
• Status: Withdrawn
• Phase: Phase 2
• Start date: April 2023
• Est. completion date: December 2024

Study information

• Verified date: May 2023
• Source: Hospices Civils de Lyon
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

SARS-CoV-2 infection is responsible for hypoxemic pneumonia, which is sometimes serious and associated with excess mortality. To date, with the exception of dexamethasone, which has shown clinical efficacy by reducing the mortality of infected patients, no other therapeutic strategy has demonstrated a curative clinical benefit, particularly in the initial stages facilitating viral eviction. .

Based on the mechanism of action and the available data, diltiazem, administered in the first days post-infection, could facilitate viral eradication in these patients through the stimulation of the innate immune response of cells of the infected respiratory epithelium, actor in the fight against SARS-CoV-2.

In this context, the investigators propose the DICOV trial, to demonstrate the ability of diltiazem to reduce the viral load more rapidly, in patients hospitalized for COVID-19 hypoxemic pneumonia.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 2024
• Est. primary completion date: October 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Male or female aged 18 or over

• SARS-CoV-2 infection proven by RT-PCR on a nasopharyngeal sample within 72 hours prior to inclusion in the study

• Onset of symptoms of viral infection = 7 days

• Hospitalization required due to hypoxemia (air saturation < 94% at rest)

• Presence of radiological pneumopathy (chest X-ray or non-enhanced thoracic CT)

• Patient affiliated to a social security scheme.

• Patient capable of giving free, informed and written consent.

• Patient with a history of SARS-CoV-2 infection may participate in the study, but this infection must not have occurred within the 3 months prior to his current hospitalization.

• Patient who has been vaccinated against SARS-CoV-2 can participate in the study (regardless of the number of doses)

• Patient not eligible for specific anti-COVID treatment authorized in France (MA or early access) and not part of the standard of care at the time of the study

• Female patient of childbearing age using effective contraception during study participation, the same applies to partners of childbearing age of male patients. Male patients must use condoms.

Exclusion Criteria:

• Need for hospitalization in intensive care unit at inclusion

• Patient with cognitive impairment, at the discretion of the investigator

• Pregnant woman (positive urine pregnancy test on inclusion) or breastfeeding

• Participation in another interventional study or being in the exclusion period from a previous study

• Patient on diltiazem therapy

• Contraindication to diltiazem

• Hypersensitivity to diltiazem or to any of the excipients

• Unaided sinus dysfunction

• Unaided 2nd and 3rd degree atrioventricular blocks

• Left ventricular failure with pulmonary stasis (cardiogenic edema)

• Severe bradycardia (= 40 beats per minute)

• In combination with: dantrolene infusion, pimozide, dihydroergotamine, ergotamine, nifedipine, ivabradine, beta blockers, antiarrhythmics, esmolol, fingolimod.

• Patient with renal, hepatic or cardiac insufficiency (at the discretion of the investigator)

• Hypersensitivity to mannitol

• Use of anti-COVID medications other than those offered in routine testing and care.

• Presence of hemodynamic instability, systolic blood pressure < 100 mmHg, presence of multi-visceral failure

• Prior respiratory pathology requiring oxygen therapy at the long-term and/or non-invasive ventilation

• Immunocompromised patients (organ transplant, allograft, under chemotherapy, under Rituximab or a history of Rituximab), for any other situation seek the advice of the coordinating investigator

• Patient under guardianship, curatorship or safeguard of justice

Related Conditions & MeSH terms

• COVID-19
• Pneumonia

Intervention

Drug:
• DILTIAZEM TEVA 60 mg or placebo
DILTIAZEM TEVA 60 mg 3 times a day during 7 days + standard of care Or placebo 3 times a day during 7 days + standard of care.

Locations

Country	Name	City	State
France	respiratory department Amiens Hospital	Amiens
France	Service de Maladies infectieuses et tropicales	Amiens
France	Département de Pneumologie, CHU Angers	Angers
France	Service de Pneumologie, CHU Besançon	Besançon
France	Service de pneumologie Hôpital Haut-Leveque	Bordeaux
France	Service de Pneumologie CHU Gabriel Montpied	Clermont-Ferrand
France	Service des Maladies Infectieuses et Tropicales	Fort-de-France
France	Maladies infectieuses et Tropicales CHU Grenoble Rhône-Alpes	Grenoble
France	Departement of Pulmonology, Croix-Rousse Hospital, Hospices Civils de Lyon	Lyon
France	Médecine Interne, Hôpital de la Croix- Rousse, HOSPICES CIVILS DE LYON	Lyon
France	Clinique des bronches, de l'allergie et du sommeil Hôpital Nord	Marseille
France	de Pneumologie Groupe Hospitalier du Havre Hôpital	Montivilliers
France	Pulmonology department CHU Montpellier	Montpellier
France	Service de Pneumologie, GHU APHP-Sorbonne Université, site Pitié Salpêtrière	Paris
France	Service Pneumologie, Hôpital BICHAT	Paris
France	Médecine interne, CHMS, Hospices Civils de Lyon	Pierre-Bénite
France	Service de pneumologie, CHLS, Hospices Civils de Lyon	Pierre-Bénite
France	Department of Pulmonology-Thoracic Oncology, University Hospital of SaintEtienne	Saint-Étienne
France	Service de pneumologie, CHRU Strasbourg	Strasbourg
France	Clinique des Voies Respiratoires Hôpital Larrey	Toulouse
France	Service des Maladies Infectieuses et du Voyageur Hôpital Gustave Dron	Tourcoing

Sponsors (2)

Lead Sponsor	Collaborator
Hospices Civils de Lyon	Signia Therapeutics

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	SARS-CoV-2 viral load decrease between D1 and D7	Dosage of the standardized SARS-CoV-2 viral load on nasopharyngeal samples on day 1 and day 7 after treatment initiation.	At day 1 and day 7 post treatment initiation.
Secondary	Time to clinical improvement	Time to clinical improvement (in days), defined as the time from randomization to an improvement of at least 2 points on a 7-point ordinal scale	Within 28 days post-randomization
Secondary	Overall survival	Percentage of patients who died between D1 and D28 of the start of treatment	at day 28
Secondary	SARS-CoV-2 viral load kinetics	Kinetics of viral load decrease by dosage of the normalized SARS-CoV-2 viral load on nasopharyngeal samples	Day 1, day 7, day 15, day 21 and day 28
Secondary	proportion of patients who are potential transfer candidates in intensive care	Percentage of patients candidates for transfer to intensive care at Day 15 of the start of treatment	At Day 15
Secondary	Tolerance of the study treatment	Occurrence of adverse events, severe adverse events and premature discontinuation of study treatment	Within 28 days after treatment initiation
Secondary	Duration of oxygen therapy	Number of days the patient was put on oxygen therapy	Within 28 days after treatment initiation
Secondary	Proportion of patients requiring assisted or non-invasive ventilation	Percentage of patients requiring assisted or non-invasive ventilation	Within 28 days after treatment initiation
Secondary	Duration of assisted or non-invasive ventilation	Number of days the patient was put on assisted or non-invasive ventilation	Within 28 days after treatment initiation
Secondary	Duration of hospitalization in intensive care unit	Number of days spent in intensive care	At day 28.
Secondary	Duration of hospitalization in intensive care unit	Number of days spent in intensive care. For patients still in intensive care on D28 this information will be collected on D90	At day 90
Secondary	Hospital length of stay	Number of days spent in hospital	At day 28.
Secondary	Hospital length of stay	Number of days spent in hospital. For patients still in intensive care on D28 this information will be collected on D90	At day 90
Secondary	Flow rate of oxygen used	Maximum oxygen rate used	Within 28 days after treatment initiation
Secondary	Extension of viral pneumonitis	Difference in extension of viral pneumonitis on comparative analysis scans performed at D1 and D28	Day 1, day 28